Nippon Shinyaku Submits NDA For MDS Drug Azacitidine In Japan
This article was originally published in PharmAsia News
Nippon Shinyaku Dec. 9 announced an NDA submission for NS-17 (azacitidine) for myelodysplastic syndrome with the Ministry of Health, Labor and Welfare
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.